Document is current
Any future updates will be listed below
-
Authors
Faisal, Fahim
Poole, Amalie C.
Danelakis, Antonios
Wergeland, Tore
Bjørk, Marte
Khanevski, Andrej N.
Kristoffersen, Espen Saxhaug
Kumelj, Tjaša
Larsen, Iben C. K.
Lunder, Oda V.
Matharu, Manjit
Nachev, Parashkev
Simpson, Melanie R.
Tronvik, Erling
Vetvik, Kjersti G.
Winsvold, Bendik S.
Øie, Lise R.
Øvrevik, Ane B.
Stubberud, Anker
-
Funding
Funding for this research was provided by:
NTNU Norwegian University of Science and Technology
- License Information
-
More Information
Article History
Received: 17 February 2026
Accepted: 23 March 2026
First Online: 30 March 2026
Declarations
:
: This study was approved by the Regional Committee for Medical and Health Research (REK 502734 and REK 574937) and the Norwegian Medical Product Agency (NOMA) (ref 22/17254-5).
: FF, AD, ANK, ESK, TK, ICL, OVL, MRS, BSW, LRØ and ABØ declare no conflict of interest related to this work. ACP has received travel grants from TEVA, AbbVie and Pfizer, and is a clinical study investigator in a trial sponsored by AbbVie (not related to present study). TW reports research grants from The Liaison Committee for Education, Research and Innovation in Central Norway (Samarbeidsorganet) and The DAM Foundation. He has received lecture honoraria from TEVA, Roche, LUNDBECK and Lilly, and is a shareholder in two medical device start-up companies (Vilje Bionics AS and Keimon Medical AS). MHB reports advisory board participation and/or speaking honoraria from Pfizer, Jazz Pharmaceuticals, Angelini Pharma, AbbVie, Lundbeck, Organon, Teva, and Eisai. Her institution and research group have received funding from valproate marketing authorisation holders for post-marketing safety studies, and from Lundbeck for a phase IV eptinezumab study. She is supported by the Research Council of Norway (grant 328615) and the Trond Mohn Foundation (grant TMF2024TMT03). MSM has served on advisory boards for AbbVie, Eli Lilly, Pfizer, Salvia and TEVA; has received payment for educational presentations from AbbVie, Eli Lilly, Organon and TEVA; has received grants from Abbott and Ehlers Danlos Society; stocks in Keilon Medical; and has a patent on system and method for diagnosing and treating headaches (WO2018051103A1, issued). PN is a shareholder in Hologen. ET has received personal fees for lectures/advisory boards: Novartis, Eli Lilly, Abbvie, TEVA, Roche, Lundbeck, Pfizer, Biogen. Consultant for and owner of stocks and IP in Man & Science. Stocks and IP in Nordic Brain Tech and Keimon Medical. Non-personal research grants from several sources, including EU, Norwegian Research Council, Dam foundation, KlinBeForsk. Commissioned research (non-personal): Lundbeck, Eli-Lilly. KGV reports advisory board participation and/or speaking honoraria from Pfizer, AbbVie, Lundbeck, Organon, Teva and Novartis. AS has received lecture honoraria from TEVA. AS is share-holder and patent holder of Nordic Brain Tech AS and the Cerebri app.
